Skip to main content
SpringerLink
Log in

Maternal Toxicity

  • Protocol
  • First Online:
Teratogenicity Testing

Part of the book series: Methods in Molecular Biology ((MIMB,volume 947))

Abstract

Although demonstration of some degree of maternal toxicity is required in regulatory developmental toxicology studies, marked maternal toxicity may be a confounding factor in data interpretation. Reduction in maternal body weight gain is the far most frequently used endpoint of toxicity, but alternative endpoints, like organ toxicity or exaggerated pharmacological response, can also be taken into consideration. The following conclusions are based on literature data and discussions at maternal toxicity workshops attended by representatives from regulatory agencies, academia, and industry: (1) Available results do not support that maternal toxicity (defined as clinical signs, decreased body weight gain or absolute body weight loss of up to 15% in rats or 7% in rabbits) can be used to explain the occurrence of major malformations. (2) There is clear evidence that substantial reductions in maternal weight gain (or absolute weight loss) are linked with other manifestations of developmental toxicity. Among these can be mentioned decreased fetal weight, and skeletal anomalies (e.g., wavy ribs) in rats and decreased fetal weights, post implantation loss, abortions, and some skeletal anomalies in rabbits. (3) There are several examples of misinterpretation among companies, where it was incorrectly expected that regulatory authorities would not label chemicals/drugs as “teratogens/developmental toxicants” because embryo fetal adverse effects were only observed at doses also causing signs of maternal toxicity. (4) Similarly, even if mechanistic studies indicate that a substance causes developmental toxicity via exaggerated pharmacological effects in the mother, such a mechanism does not automatically negate the observed fetal adverse effects.

From a regulatory perspective, an observed developmental toxic finding is considered to be of potential human relevance (even if it is mediated via maternal pharmacological effects or occur at doses causing signs of maternal toxicity) unless the company can provide appropriate mechanistic and/or other convincing evidence to the contrary.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ICH (2005) Guidance to industry: detection of toxicity to reproduction for medicinal products & toxicity to male fertility S5(R2)

    Google Scholar 

  2. US EPA (1998) Health effects test guidelines. OPPTS 870.3700. Prenatal developmental toxicity study. http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/EPA/EPA_870_3700.pdf. Accessed 24 Aug 2011

  3. OECD (2001) OECD Test Guideline for the Testing of Chemicals. 414 Prenatal ­developmental toxicity study. http://www.oecd-ilibrary.org/environment/test-no-414-prenatal-development-toxicity-study_9789264070820-en;jsessionid=3s08ej79xtfen.epsilon. Accessed 14 Oct 2012

  4. US FDA Center for Food Safety and Applied Nutrition (2000) Toxicological principles for the safety assessment of food ingredients. Chapter IV.C.9.b. Guidelines for Developmental Toxicity Studies

    Google Scholar 

  5. Khera KS (1984) Maternal toxicity—a possible factor in fetal malformations in mice. Teratology 29:411–416

    Article  PubMed  CAS  Google Scholar 

  6. Khera KS (1985) Maternal toxicity: a possible etiological factor in embryo-fetal death and fetal malformation of rodent-rabbit species. Teratology 31:129–153

    Article  PubMed  CAS  Google Scholar 

  7. Hood RD, Miller DB (2006) Maternally-mediated effects on development. In: Hood RD (ed) Developmental and reproductive toxicology, a practical approach, 2nd edn. CRC, Boca Raton, pp 93–124

    Google Scholar 

  8. Beyer B, Chernoff N, Danielsson BR et al (2011) ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation. Birth Defects Res B Dev Reprod Toxicol 92:36–51

    Article  PubMed  CAS  Google Scholar 

  9. Khera KS (1987) Maternal toxicity in humans and animals: effects on fetal development and criteria for detection. Teratog Carcinog Mutagen 7:287–295

    Article  PubMed  CAS  Google Scholar 

  10. Kavlock RJ, Chernoff N, Rogers EH (1985) The effect of acute maternal toxicity on fetal development in the mouse. Teratog Carcinog Mutagen 5:3–13

    Article  PubMed  CAS  Google Scholar 

  11. Chernoff N, Setzer RW, Miller DB et al (1990) Effects of chemically induced maternal toxicity on prenatal development in the rat. Teratology 42:651–658

    Article  PubMed  CAS  Google Scholar 

  12. Chahoud I, Ligensa A, Dietzel L et al (1999) Correlation between maternal toxicity and embryo/fetal effects. Reprod Toxicol 13:75–81

    Google Scholar 

  13. Fleeman TL, Cappon GD, Chapin RE et al (2005) Effects of feed restriction during organogenesis on embryo-fetal development in the rat. Birth Defects Res B Dev Reprod Toxicol 74:42–449

    Article  Google Scholar 

  14. Petrere JA, Rohn WR, Grantham LE et al (1993) Food restriction during organogenesis in rabbits: effects on reproduction and the offspring. Fundam Appl Toxicol 21:517–522

    Article  PubMed  CAS  Google Scholar 

  15. Cappon GD, Fleeman TL, Chapin RE et al (2005) Effects of feed restriction during organogenesis on embryo-fetal development in the rabbit. Birth Defects Res B Dev Reprod Toxicol 74:424–430

    Article  PubMed  CAS  Google Scholar 

  16. Clark RL, Robertson RT, Peter CP et al (1986) Association between adverse maternal and embryo-fetal effects in norfloxacin-treated and food-deprived rabbits. Fundam Appl Toxicol 7:272–286

    Article  PubMed  CAS  Google Scholar 

  17. Organization for Economic Cooperation and Development (OECD) (2007) Draft guidance document on mammalian reproductive toxicity testing and assessment. OECD Environment, Health and Safety Publications, Series on Testing and Assessment, No. 43. http://www.oecd.org/dataoecd/5/61/39813058.pdf. Accessed 25 Aug 2011

  18. US Environmental Protection Agency (EPA) (1991) Guidelines for developmental toxicity risk assessment. Fed Regist 56:63798–63826

    Google Scholar 

  19. Chernoff N, Rogers EH, Gage MI et al (2008) The relationship of maternal and fetal toxicology bioassays with notes on the biological significance of the “no observed adverse effect level”. Reprod Toxicol 25:192–202

    Article  PubMed  CAS  Google Scholar 

  20. Matuzawa T, Nakata M, Goto I et al (1981) Dietary deprivation induces fetal loss and abortion in rabbits. Toxicology 22:255–259

    Article  Google Scholar 

  21. Franklin JB, Brent RB (1964) The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old. J Morphol 115:273–290

    Article  PubMed  CAS  Google Scholar 

  22. Webster WS, Abela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81:215–228

    Article  PubMed  CAS  Google Scholar 

  23. Danielsson BR, Reiland S, Rundqvist E et al (1989) Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology 40:351–358

    Article  PubMed  CAS  Google Scholar 

  24. Danielsson BR, Danielson M, Reiland S et al (1990) Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators. Teratology 41:185–193

    Article  PubMed  CAS  Google Scholar 

  25. Yoshida T, Kanamori S, Hasegawa Y (1988) Hyperphalangeal bones induced in rat pups by maternal treatment with nifedipine. Toxicol Lett 40:127–132

    Article  PubMed  CAS  Google Scholar 

  26. Danielsson BR, Webster WS (1997) Cardiovascular active drugs. In: Kavlock RJ, Daston G (eds) Drug toxicity in embryonic development II; advances in understanding mechanisms of birth defects: mechanistic understanding of human developmental toxicants. Springer, Berlin, pp 161–190

    Google Scholar 

  27. Clark RL, Robertson RT, Minsker DH et al (1984) Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits. Teratology 30:319–332

    Article  PubMed  CAS  Google Scholar 

  28. Fawcett LB, Buck SJ, Brent RL (1998) Limb reduction defects in the A/J mouse strain associated with maternal blood loss. Teratology 58:183–189

    Article  PubMed  CAS  Google Scholar 

  29. Daston GP, Overmann GJ, Taubeneck MW et al (1991) The role of metallothionein induction and altered zinc status in maternally-mediated developmental toxicity. Comparison of the effects of urethane and styrene in rats. Toxicol Appl Pharmacol 110:450–463

    Article  PubMed  CAS  Google Scholar 

  30. Daston GP, Overmann GJ, Baines D, Taubeneck MW et al (1994) Altered Zn status by alpha-hederin in the pregnant rat and its relationship to adverse developmental outcome. Reprod Toxicol 8:15–24

    Article  PubMed  CAS  Google Scholar 

  31. Schettler T (2008) New conceptual frameworks and challenges in the investigation and practice of environmental reproductive health. Fertil Steril 89:25–26

    Article  Google Scholar 

  32. European Public Assessment Report on revlimid (14 August 2008; updated 17 May 2010). Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/revlimid/revlimid.htm. Accessed 25 Aug 2011

  33. Polak S, Wisnowska B, Brandys J (2009) Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs’ cardiotoxic properties. J Appl Toxicol 29:183–206

    Article  PubMed  CAS  Google Scholar 

  34. Danielsson BR, Danielsson C, Nilsson M (2007) Embryonic cardiac arrhythmia and generaton of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs. Reprod Toxicol 24:42–56

    Article  PubMed  CAS  Google Scholar 

  35. Karlsson M, Danielsson BR, Nilsson M et al (2007) New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potential. Curr Pharm Des 13:2979–2988

    Article  PubMed  CAS  Google Scholar 

  36. Sköld AC, Danielsson C, Linder B et al (2002) Teratogenicity of the IKr-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol 16:333–342

    Article  PubMed  Google Scholar 

  37. Nilsson MF, Danielsson C, Sköld AC (2010) Astemizole: improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reprod Toxicol 29:156–163

    Article  PubMed  CAS  Google Scholar 

  38. International Conference on Harmonization (ICH) (2009) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, M3 (R2)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmanet I3, Stockholm, Sweden

    Bengt R. Danielsson

Authors
  1. Bengt R. Danielsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bengt R. Danielsson .

Editor information

Editors and Affiliations

  1. CiToxLAB, BP 563, Evreux, 27005, France

    Paul C. Barrow

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Danielsson, B.R. (2013). Maternal Toxicity. In: Barrow, P. (eds) Teratogenicity Testing. Methods in Molecular Biology, vol 947. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-131-8_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-131-8_24

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-130-1

  • Online ISBN: 978-1-62703-131-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation